Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment

Autor: Katsumi Fukamachi, Harutoshi Matsumoto, Masumi Suzui, Takao Nitanda, Saeko Ando, Mitsuru Futakuchi, Eri Yoshimoto
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Osteolysis
medicine.medical_treatment
Cell
lcsh:Chemistry
osteoclastogenesis inhibitory factor
Mice
0302 clinical medicine
Tumor Microenvironment
Medicine
Neoplasm Metastasis
lcsh:QH301-705.5
Spectroscopy
bone metastasis
Mice
Inbred BALB C
Mammary tumor
biology
RANKL
Bone metastasis
General Medicine
Recombinant Proteins
Computer Science Applications
medicine.anatomical_structure
Cytokine
030220 oncology & carcinogenesis
Neoplastic Stem Cells
Cytokines
Female
bone microenvironment
cancer stem cell
mammary tumor
Bone Neoplasms
Article
Catalysis
Inorganic Chemistry
03 medical and health sciences
Cancer stem cell
Cell Line
Tumor
Animals
Humans
Physical and Theoretical Chemistry
Molecular Biology
Cell Proliferation
Dose-Response Relationship
Drug
business.industry
Cell growth
Organic Chemistry
Osteoprotegerin
Mammary Neoplasms
Experimental
medicine.disease
030104 developmental biology
lcsh:Biology (General)
lcsh:QD1-999
Cancer research
biology.protein
business
Zdroj: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 19, Iss 3, p 888 (2018)
International Journal of Molecular Sciences; Volume 19; Issue 3; Pages: 888
ISSN: 1661-6596
Popis: We examined the effects of recombinant human osteoclastogenesis inhibitory factor (hOCIF) on osteolysis, proliferation of mammary tumor cells, and induction of cancer stem cells (CSCs) in the tumor-bone and tumor-subcutaneous microenvironments (TB- and TS-microE). Methods: Mouse mammary tumor cells were transplanted onto the calvaria or into a subcutaneous lesion of female mice, creating a TB-microE and a TS-microE, and the mice were then treated with hOCIF. To investigate the preventive effects of hOCIF, mice were treated with hOCIF before tumor cell implantation onto the calvaria (Pre), after (Post), and both before and after (Whole). The number of CSCs and cytokine levels were evaluated by IHC and ELISA assay, respectively. Results: hOCIF suppressed osteolysis, and growth of mammary tumors in the TB-microE, but not in the TS-microE. In the Pre, Post, and Whole groups, hOCIF suppressed osteolysis, and cell proliferation. hOCIF increased mouse osteoprotegrin (mOPG) levels in vivo, which suppressed mammary tumor cell proliferation in vitro. These preventive effects were observed in the dose-dependent. hOCIF did not affect the induction of CSCs in either microenvironment. Conclusion: While receptor activator of NF-κB ligand (RANKL) targeting therapy may not affect the induction of CSCs, RANKL is a potential target for prevention as well as treatment of breast cancer bone metastasis.
International Journal of Molecular Sciences, 19(3), 888; 2018
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje